Abstract. – Despite recent advances in the treatment of breast cancer (BC), it still remains as a prevalent and deadly cancer in the world. Given that BC is a heterogeneous disease, it is necessary to clarify molecular mechanisms in tumor cells to improve various therapy outcomes and overcome therapy resistance. Autophagy represents one of the most important intracellular degradation pathways involved in diverse biological processes and plays an important bi-directional role in tumor formation and progression. Among the several mechanisms that affect autophagy, microRNAs (miRNAs) play a crucial role as gene regulators. Several in vivo and in vitro studies have reported multiple miRNAs regulating autophagy in BC that affect tumor initiation, progression, and response to various therapies. In the present review, we highlighted the mechanisms through which miRNAs regulate autophagy in BC and their potential use as therapeutic targets.

Key Words: Autophagy, MicroRNA, Breast cancer, Chemotherapy, Radiotherapy.

Introduction

Despite all the efforts that have been made in recent years for the prevention and treatment of BC, this disease is currently the most widespread cancer with the highest death rate in the world which indicates a need to explore the molecular details of tumor cells activities in more detail.

As a cell recycling mechanism, autophagy plays an important role in maintaining cells’ homeostasis and basic activities which have been attracted attention in recent years in cancer research. Considering autophagy’s quality control and stress-management roles in cells, any disorder in this process can play a role in cancer initiation and progression. However, according to the results of various studies, an ambiguous relationship between autophagy and carcinogenesis has been observed, which has necessitated further research.

MiRNAs are among the factors that have been considered as a tool for detection, treatment, and monitoring cancer patients. These molecules, as regulators of gene expression, affect a wide range of cellular events and are among the vital factors in some events including cancer. In recent years, studies have been shown the regulatory relation between miRNAs and the autophagy process.

Given that autophagy and miRNAs have both been linked to tumorigenesis and miRNAs have a regulatory effect on autophagy, it seems plausible to use autophagy-regulating miRNAs as diagnostic and therapeutic targets. In this review, we will provide a comprehensive description of autophagy, followed by a discussion on autophagy-regulating miRNAs in BC, especially those involved in responding to different therapies in BC.

Breast Cancer

BC is the most prevalent and deadliest cancer globally with more than 2 million new cases being diagnosed in 2019. According to statistics, eight out of one woman (13%) will get BC, and 35 out of one woman (3%) will pass away due to the BC during her lifetime. Age, gender, family history, gene mutations, radiation exposure, periodontitis, medical intervention such as hormonal replacement therapy, and microbiota...
are all risk factors for BC. The presence or absence of molecular markers, as well as estrogen or progesterone receptors (hormone receptors) and human epidermal growth factor 2 (EGFR2 or HER2), cause molecular subtypes inclusive of luminal subtypes A (HR+/HER2-), B (HR+/HER2+), HER2-enriched (high expression level of EGFR2) and triple-negative tumors (TNBC) (HR- and HER2-). These subtypes cause high heterogeneity and make the necessity for various treatment options. Although usage of various therapy options including surgical resection, radiotherapy, chemotherapy, targeted therapy, immunotherapy, and systemic therapy have lowered the mortality rate, there are still many barriers to the treatment of patients with BC, which limits the success of the therapy.

**MicroRNAs**

MiRNAs as a type of small non-coding RNAs play pivotal roles in regulating gene expression in a target-specific manner based on the extent of complementarity with targeted miRNAs. Their regulatory effects are exerted by mRNA decay or translational repression. Considering their effect on the gene or protein expression, various cellular functions such as metabolism, proliferation, differentiation, apoptosis, survival, and stress responses in different cell types are affected by miRNAs. There is a link between dysregulation in miRNAs expression patterns and many malignancies. Depending on the mRNA they are targeted during carcinogenesis, they operate as an oncomiR or tumor suppressor. All stages of tumorigenesis including initiation, progression, spreading, and even the response to therapies can be affected by changes in miRNA levels. The first relation between miRNAs and BC was shown in 2005 and since then many studies have been conducted and have shown that miRNAs have the potential to be used as diagnostic, prognostic, and therapeutic biomarkers in BC.

**Autophagy**

The cornerstone of biological activities in cells is the maintenance of physiological homeostasis via biosynthesis and degradation. Autophagy is a conserved and regulated cellular mechanism that helps to degrade and recycle cytoplasmic components and organelles in organisms ranging from yeast to mammals. For the first time, it was suggested by Christian de Duve in 1963 as the cellular process in which the bilateral membrane vesicle called the autophagosome, engulfs intracellular contents and delivers them to the lysosome for digestion. Due to this action, not only cellular substances and damaged organelles are removed, but also the materials needed by the cell are recycled and energy homeostasis is maintained. Autophagy is active in most cells at a low level regulating cell metabolism by eliminating damaged proteins and organelles, called basal autophagy. Furthermore, stress conditions such as starvation, unfolded protein response, hypoxia, DNA damage, viral infection, growth factor depletion, etc. can initiate autophagy which is called induced autophagy to respond to the needs of the cell. There are several biological functions for which autophagy is critical ranging from embryonic development to cell death in a way it is suggested as programmed cell death type II or autophagic cell death (ACD). There is a strong association between autophagy and numerous cellular signaling pathways. In response to stimulus or stressful conditions autophagy-related genes (ATGs) are activated and contribute to the formation of autophagosome and fusion with the lysosome. Recent studies have shown what was thought to be a non-selective process of autophagy can be a selective one under nutrient-rich conditions (macroautophagy), and there are different forms of selective autophagy, according to the targets, which are: nucleophagy, ER-phagy, mitophagy, ribophagy, lipophagy, glycophagy, etc. Selective autophagy is facilitated by the presence of receptors such as p62 (sequestosome-1 or SQSTM1), OPTN (optineurin), CALCOCO2 (calcium-binding and coiled-coil domain-containing protein 2), and Bnip3L (BCL2-interacting protein 3-like).

There is evidence that mutation in these genes has a relation with human disorders. An altered autophagic process is associated with cardiovascular diseases, autoimmune diseases, neurodegenerative disorders, infections, myopathies, diabetes, and cancer.

**Types of Autophagy**

Eukaryotic cells administer three types of autophagy based on the delivery pathway of targets to lysosomes: macroautophagy (MA), microautophagy (MI), and chaperone-mediated autophagy (CMA). MA is the most intensively studied type of autophagy in which time-worn proteins and organelles are engulfed by autophagosomes. Subsequently, lysosomes combine with the created autophagosomes and form autophagolysosomes.
(or autolysosomes) which provide a milieu for the degradation of proteins and organelles. Other types of autophagy differ in the manner in which the material is delivered to the lysosome as in MI, the lysosome itself engulfs abundant, small cytoplasmic cargoes. In CMA, target substrates tagged with special C-terminal KFERQ motifs are recognized and transferred into the lysosomes by Hsc70 (Heat shock cognate protein of 70 kDa) and endosomal sorting complexes are required for transport I and III (ESCRT/III). Delivery of substrates to lysosomes occurs through the binding of Hsc70 to the lysosome-associated membrane glycoprotein type 2A (LAMP2A). MA represents the canonical pathway of autophagy and has been more intensively decoded, we will focus on this type and use the term “autophagy” instead of MA in this review.

**Autophagy Mechanisms**

The mechanism of MA consists of several stages and the participation of numerous factors. The stages include initiation, nucleation, elongation, autophagosomal formation and maturation, lysosomal fusion, degradation, and recycling.

**Initiation**

Intracellular and extracellular stimuli bring up-stream autophagy factors and substrates together in a specific site called pre-autophagosomal structure (PAS) for autophagosomal formation. This stage is governed by the complex of Unc-51-like kinases (ULK) which is recruited and incorporated into PAS. One of the most important regulatory and influential factors in this stage is the mechanistic target of rapamycin (mTOR) complex 1 (mTORC1). In normal conditions, mTOR activation causes autophagy inhibition through the phosphorylation of ATG13 and blockage of its link to ULK1 to form the ULK complex. In stressful conditions, mTOR is suppressed and causes the activation ofULK1 and ULK2. Ultimately, ATG13 along with ATG101, ATG9A, and the focal adhesion kinase (FAK) family kinase-interacting protein 200 (FIP200) form a ULK complex and anchored it to the PAS.

**Nucleation**

ULK complex causes phosphorylation and activation of class III phosphatidylinositol 3-kinase (PI3K) complex including Beclin1/Vps34/ATG14L/Vps15/UVRAG/AMBRA1 which produce phosphatidylinositol 3-phosphate (PI3P). Following, the isolation bilayer membrane called phagophore is formed and enriched by phosphatidylinositol 3-phosphate (PI3P) and then is extended to a double-membrane vesicle called omegasome. According to studies, these membranes have been found to come from the ER, Golgi apparatus mitochondria, and plasma membrane. Along with the formation of the phagophore, ATG proteins are recruited and help to enlarge the membrane. Bcl-2 and Bcl-XL can bind to Beclin1 and inhibit this step of the autophagy process. This inhibitory effect is only related to the ER-localized Bcl-2, not the mitochondrial Bcl-2.

**Elongation**

As the membrane expands, several ATGs are joining it. Two conjugation systems including ATG12/ATG5/ATG16L1 and microtubule-related protein light chain 3 (LC3) are essential pathways to regulate elongation. ATG7 activates ATG12 which moves towards ATG10 and via its help is conjugated with ATG5 and makes ATG12/ATG5 complex. Then, ATG16L1 through non-covalent interaction binds to ATG12/ATG5 complex. Moreover, ATG4 cleaves LC3 at carboxy terminus to produce LC3-I as a cytosolic free agent which is then conjugated to phosphatidylethanolamine (PE) of the membrane of the autophagosome with the help of ATG7 and ATG3. Ultimately, the LC3-II complex is produced which its presence in phagophore helps to autophagosome formation.

**Autophagosomal Maturation**

During the autophagosome maturation ATG5, ATG12, and ATG16 and after maturation LC3-II detaches. Then, syntaxin17 (STX17) is recruited to the autophagosome membrane and maturation is completed.

**Lysosomal Fusion, Degradation, and Recycling**

For fusion of the autophagosome with lysosome presence of several proteins including soluble N-ethylmaleimide-sensitive factor activating protein receptors (SNARE) complexes (VAMP7, VAMP3, VAMP8, and STX17), Rab proteins, and integral lysosomal proteins (LAMP-2) are required. Among these proteins, STX17 is the most important one in a way that fusion starts when the STX17 presents on the surface of the matured autophagosome. During fusion, the structure of the inner membrane is degraded and the contents are exposed to lysosomal enzymes, and the degradation process begins.
Autophagy Inducers

Autophagy is a mechanism by which cells adapt to environmental and nutritional stresses. Mutually, nutritional starvation and excess nutrient stress can promote autophagy. Energy starvation activates autophagy via the AMP-activated protein kinase (AMPK) signaling pathway. In this pathway, starvation activates LKB1 (liver kinase B1)-AMPK which can in turn directly activate the ULK-1 complex. LKB1-AMPK can also suppress mTOR through TSC1-TSC2 (tuberous sclerosis complex 1-2) activation. Both of these routes cause autophagosome formation. Also, DNA damage and hypoxia activate the AMPK pathway which leads to ULK-1 complex activation. It was revealed that elevated concentrations of glucose, also induce autophagy mainly through the reactive oxygen species (ROS) pathway. On the other hand, mTORC1 has a major role in autophagy induction in response to amino acid deprivation. Excessive accumulation of misfolded proteins in the endoplasmic reticulum (ER) can lead to ER stress. ER stress is one of the activating mechanisms of autophagy. This type of stimulation occurs via activation of ER membrane-associated proteins; protein kinase R-like kinase (PERK), endoplasmic reticulum inositol-requiring enzyme 1 (IRE1), and activation of transcription factor 6 (ATF6). PERK effects are due to the regulatory effects on LC3, ATG5, and eukaryotic initiation factor2 (eIF2) which finally inhibit the synthesis of unfolded or misfolded proteins. The second mechanism is performed by disassembling BCL2 protein from Beclin1 through activating the IRE1. ATF6 as a transcription factor increases the expression of the ER chaperone, HSPA5 which then activates AKT. Growth factors as other regulators of autophagy, trigger the AKT pathway through activating PI3K which inhibits the TSC1-TSC2 complex. TSC1-TSC2 suppression countermands mTOR inhibition which enhances mTOR activity resulting in autophagy inhibition. Consequently, PTEN (phosphatase and tensin homologue) can disable this pathway via blocking PI3K activation and reverse the effect of mTOR inhibition.

Autophagy and Cancer

The first finding indicating the relation between autophagy and cancer was the presence of deleterious mutations in the Beclin-1 in breast, prostate, and ovarian cancer patients. In the early stages of cancer, autophagy shows tumor-suppressor effects via oncoprotein degradation, oxidative stress elimination, maintaining genomic integrity, defenses against bacterial and viral pathogens, and participation in the development of immune responses. Hence, tumor initiation and progression are inhibited by autophagy at the early stages of cancer. Another tumor suppression effect of autophagy is its role in maintaining genomic integrity. Some disorder in the autophagy process causes DNA damage and increases cancer risk. However, in advanced stages where the hypoxia becomes dominant, autophagy functions providing the necessary materials for cells to deal with the hypoxia and nutrients cause an improvement in tumor cells survival, metastasis, and suppression apoptosis. With more details, tumor cells usually have a problem supplying their needful glucose. In this condition AMPK-mediated autophagy is activated in tumor cells, also blockage of glycolysis due to lack of glucose causes ER stress which activates autophagy. In the same way, amino acid depletion activates AMPK-mediated autophagy. The mentioned conditions lead to autophagy-mediated cell survival which promotes tumor growth. Therefore, autophagy functions as a double-edged sword based on type, stage, and genetic context of tumor cells because as mentioned above it can lead tumor cells to autophagy-mediated cell survival and enhance tumor development, in contrast, it can also steer cancer cells to autophagy-mediated cell death and block tumor development.

In clinical application, chemotherapeutic agents like 5-fluorouracil (5-FU), gemcitabine, and cisplatin cause DNA damage and induce AMPK-mediated autophagy in cancer cells that lead to cancer cell survival. Also, exposing infrared radiation (IR) to tumors activates autophagy in tumor cells and makes them survive via DNA damage and mTOR inhibition. However, in some cases usage of conventional cancer treatments causes activation of autophagy and developing drug resistance. In consequence, targeting autophagy was suggested as a therapeutic option in cancer therapies. Using a mixture of chemotherapeutics and autophagy inhibitors such as Bafilomycin, Chloroquine (CQ), and 3-methyladenine (3MA) can overcome drug resistance and block autophagy-mediated cell survival and steer cancer cells to cell death.
in the onset and progression of BC affect autophagy through different pathways. For example, in the early stages of BC the activity of tumor suppressor genes, p53 and PTEN, trigger autophagy and suppress tumorigenesis while along with tumor progression activation of oncogenes, Bcl-2 and PI3K/AKT, restrain stress responses, and suppress autophagy. Furthermore, studies have been shown that in advanced stages of BC, oncogenic mTOR-activating proteins were upregulated. On the other hand, mutations in genes expressing proteins involved in the early stages of autophagy such as Beclin-1 or BECN1 have been reported in almost all cases of BC. Conventional approaches and even new targeted drugs such as anti-HER2 drugs, PI3K/AKT inhibitors, CDK4/6 inhibitors, and immune checkpoint inhibitors can also affect the autophagy pathway and result in treatment resistance in some cases. In light of these findings, autophagy inhibitors have been suggested as an alternative therapeutic option in BC patients, but more studies are needed. Given that the relationship between autophagy and BC has been thoroughly studied in another review article, we will not elaborate further here.

**Autophagy and MiRNAs**

Numerous studies have shown that autophagy and miRNAs have a bilateral relationship. Autophagy performs an important role in maintaining the homeostasis of miRNAs and miRNAs have regulatory effects on autophagy both in vivo and in vitro due to their gene expression regulation effects on ATGs and proteins involved in signaling pathways related to autophagy. Depending on whether the tumor cells are under metabolic or therapeutic stress, miRNAs-mediated autophagy can have either pro-survival or pro-death effects. The relation between miRNAs and autophagy not only affects the different stages of tumor growth and development but in the same way affects the response to different cancer therapies such as radiotherapy and chemotherapy. For the first time in 2009, Zhu et al showed that miR-30a downregulates the expression level of Beclin-1 to suppress rapamycin-induced autophagy in tumor cells and further studies have shown that miRNAs can affect all stages of autophagy. This regulation can occur by both types of tumor-suppressor and oncomiRs, leading to activation or inhibition of autophagy. In squamous cell carcinoma miR-885–3p targets ULK2 and inhibits autophagy in response to cisplatin treatment. Under hypoxic conditions of hepatocellular carcinoma (HCC) cells, miR-375 decreases ATG7 and inhibits autophagy in vitro and in vivo. MiR-30d suppresses Beclin-1 and increases the response to cisplatin in thyroid carcinoma cells. MiR-140-5p by targeting ATG12 causes an inhibition of autophagy which suppresses the survival of colorectal cancer stem cells. In cervical cancer, increased expression of miR-224-3p inhibits autophagy via targeting FIP200. MiR-17 can inhibit the formation of autophagolysosome by targeting Rab7 GTPase members. A study by Yuan et al showed that increasing the expression level of tumor-suppressor miR-375 in gastric cancer inhibits autophagy via targeting the mTOR pathway. In another study on gastric cancer, increasing the expression level of miR-21 led to inhibition of autophagy via the PI3K/Akt/mTOR pathway which decreased cisplatin resistance. These are just a few of the many studies that have been conducted on the first step of autophagy and they are still ongoing revealing other miRNAs regulatory effects on different steps of autophagy.

**Autophagy and MiRNAs in BC**

Like other cancers, the autophagy process in BC is affected by changes in the expression level of miRNAs and several studies have been reporting various autophagy regulating miRNAs at many points in BC. MiR-20a and miR-20b involvement in autophagy regulation via targeting FIP200/ RB1CC1, as an important part of the ULK complex, was shown in MCF-7 and MDA-MB-231 cells by Li et al. The study revealed that overexpression of miR-20a and miR-20b inhibits basal and rapamycin-induced autophagy which causes inhibition in cancer progression. However, in another study, Liu et al showed the ability of miR-20a to inhibit basal and nutrient starvation-induced autophagy via targeting Beclin-1, ATG16L1, and SQSTM1 in MDA-MB-231 and MCF-7 cells and unexpectedly improved tumor initiation and growth. MiR-23a is among miRNAs involved in the regulation of autophagy in BC by targeting X-linked inhibitor of apoptosis (XIAP) as one of the autophagy inhibitor proteins in the cell. MiR-92b has been introduced as a tumor suppressor in BC through the inhibition of viability and invasion. Autophagy-inducing stimuli, starvation, and rapamycin cause overexpression of miR-92b that negatively regulates the histone methyltransferase enhancer of zeste homolog 2 (EZH2) which leads to promotion of autophagy. Overexpression of miRNA-96-5p inhibits autophagy and apoptosis and enhances tumorigenesis.
Autophagy-regulating microRNAs: two-sided coin in the therapies of breast cancer

of human BC cells. Furthermore, upregulation of miR-96-5p suppresses autophagy through inhibiting LC3II production and degradation of p62. This inhibitory effect of miR-96-5p happens through targeting forkhead box protein O1 (FOXO1). Shi et al80 showed that increased expression of miR965p not only improves proliferation, migration, and invasion but also inhibits basal and starvation-induced autophagy through targeting FOXO1 in MCF7 and MDA-MB-231 cells. Frankel et al82 conducted an in vitro and in vivo study and found miR-101 as one of the effective inhibitors of basal-, etoposide- and rapamycin-induced autophagy in BC. They revealed ATG4D, STMN1, and Rab5A as targets of miR-101. Ai et al83 observed a relation between decreased expression of miR-107 and suppressed autophagy process and tumor cell proliferation via targeting high mobility group protein B1 (HMGB1). They suppressed the expression of HMGB1 and detected increased expression of p62 protein and decreased Beclin1 protein in MDA-MB-231 and MDA-MB-453 BC cells.

Decreased expression of miR-124-3p on BC tissues and cell lines was shown in a study by Zhang et al84. They showed that miR-124-3p affects the autophagy process via targeting Beclin1. Increased expression of miR-224-5p in metastatic and non-metastatic BC cell lines was reported to inhibit autophagy through suppressing the TGF-β/Smad4 signaling pathway which is one of the autophagy activating pathways that increased ATG5, ATG6, and ATG7 proteins85. MiR-372 suppresses autophagy and tumor growth in BC by targeting p6286. An in vitro study described that down-regulation of miR-486-5p would increase autophagy through targeting FOXO1 in MCF7 and MDA-MB-231 cells. These findings suggest the potential role of miRNAs in regulating autophagy in BC.

Effects of Autophagy and miRNAs on Hypoxia of BC

Hypoxia is one of the pathologic features that affects various tumor processes such as metastasis, angiogenesis, recurrence, and chemoresistance in BC80. In response to hypoxia generated in the tumor microenvironment, tumor cells increase the expression of hypoxia-inducible factor (HIF)-1α which regulates genes and intracellular pathways including hypoxia-inducible factor (HIF)-1α-mediated downregulation in the expression level of miR-137 under hypoxia conditions. Following miR-137 restoration, mitophagy/autophagy is inhibited via targeting FUN14 domain-containing protein 1 (Fundc1) and promotes tumorigenesis. Fundc1 as a mitochondria membrane protein promotes autophagy and upregulates the expression of Beclin1, ATG5, and ATG7.

Effects of Autophagy and miRNAs on Chemotherapy of BC

One of the most fundamental therapies for patients with BC is chemotherapy, whether it is used alone or in combination with another treatment method. Different types of chemotherapy drugs with different mechanisms are used in BC including anthracyclines (doxorubicin and epirubicin), taxanes (paclitaxel and docetaxel), platinum (cisplatin), etc. Despite the promising results
of chemotherapy in reducing the growth and development of tumor cells, resistance to these agents reduces the therapeutic effects and also leads to tumor metastasis and recurrence. The results of various studies revealed an association between autophagy and drug resistance not only in BC but also in different types of other cancers. This includes colorectal, bladder, ovarian, prostate, osteosarcoma, and malignant glioma.

Generally, three types of association between autophagy and drug resistance have been observed in BC. First, autophagy by protecting tumor cells against external stressors, such as chemotherapy drugs, develops resistance. Indeed, in some cases inhibition of autophagy reversed the resistance to chemotherapy drugs. This type of autophagy is designated cytoprotective autophagy that acts as an important inhibitory factor in the treatment of BC patients. Unlike the first case, some studies have shown that increased autophagy enhances the sensitivity of BC cells to chemotherapy drugs and promotes different types of cell death. Furthermore, any change in different stages of autophagy can affect the process of drug resistance in BC. MiRNAs are one of the critical factors involved in regulating the sensitivity of tumor cells to several chemotherapy drugs. They can increase the sensitivity or the resistance of BC tumor cells in response to chemotherapeutic agents due to their effects on the proteins involved in the autophagy process.

Resistance to paclitaxel (PTX) is among those reasons for death associated with treatment failure in BC patients. Shi et al. demonstrated that up-regulation of miR-129-5p increased paclitaxel sensitivity of MCF-7 cells which led to inhibition of autophagy and promoting apoptosis by targeting HMGB1. The presence of BCSCs causes chemoresistance, recurrence, and metastasis of tumor cells. Ueda et al. showed that miR-27a acts as a master regulator for BCSCs through regulating autophagy. Overexpression of miR-27a increased the sensitivity of MCF-7 and MDA-MB-231 cells to PTX and doxorubicin (DOX) via suppressing autophagy and affecting p62. The involvement of miR-18a in PTX resistance was shown in TNBC cells. PTX resistant cell line, MDA-MB-231/PTX cells, showed a higher level of miR-18a and autophagy in comparison with MDA-MB-231 cells. The study revealed that overexpression of miR-18a inhibited mTOR expression which further increased autophagy and

Figure 1. The roles of miRNAs in regulating the autophagy process in breast cancer. Upon the presence of stimuli, the autophagy process is induced and consists of several different stages; initiation, nucleation, elongation, autophagosomal formation and maturation, lysosomal fusion, degradation, and recycling. miRNAs exert their dual regulatory effects by affecting the expression of components involved in different stages of autophagy. In the figure, the proteins involved in the stages of autophagy are shown in different colors, and their regulating miRNAs are shown in pink boxes.
resistance against paclitaxel. Moreover, usage of autophagy inhibitor, Bafilomycin A1, increased apoptosis and sensitivity to PTX107.

It has been shown that miR-489 has tumor suppressor effects in BC and inhibits the autophagy process108. Soni et al109 showed that suppressing autophagy through the restoration of miR-489 in the BC cell line increased the sensitivity toward DOX via targeting lysosomal protein transmembrane 4 beta (LAPTM4B) as one of the important factors in autophagosome maturation in vivo and in vitro. Furthermore, Liang et al110 reported that upregulation of miR-142-3p as a tumor suppressor miRNA in BC inhibited autophagy and improved the chemosensitivity toward DOX through the targeting HMGB1 in the MCF-7 cell line. They showed that DOX-resistant cells had low expression of miR-142-3p and a high level of autophagy.

Regarding the second relation between autophagy and drug resistance, in an in vitro study on HS578T cell line, overexpression of miR-181a-5p negatively regulated vitamin D receptor (VDR) as an autophagy regulator protein which increased autophagy and then improved sensitivity to cisplatin111. In a similar study, the usage of isoliquiritigenin (ISL) as an anti-cancer agent, repressed miR-25 expression. Upregulation of miR-25 suppressed autophagy through targeting ULK1 and improved the chemoresistance in epirubicin-resistant BC cells (MCF-7/ADR)112. Furthermore, in a study by Li et al113 increased expression of miR-125b-5p enhanced autophagy via negative regulation of peptidylarginine deimination 2 (PAD2) enzyme which has an inhibitory effect on mTOR. Increased autophagy further increased the sensitivity to tamoxifen and improved docetaxel effects as combination therapy on the tamoxifen-resistant cell line.

**Effects of Autophagy and MiRNAs on Radiotherapy of BC**

One of the most important treatment modalities used for BC patients is radiotherapy, which leads to killing tumor cells via generating oxidative damage, membrane permeability, chromosome aberrations, metabolic imbalances, and activation of signaling pathways including apoptosis and autophagy. Indeed, DNA damage, ER stress, dysfunctional mitochondria, and elevated Ca2+ levels are among the causes of radiation-induced autophagy in tumor cells114. Furthermore, radiotherapy through modulation of the immune system and tumor microenvironment has anti-cancer effects. Recent studies show that radiation-induced autophagy via impressing antigen presentation, generating damage-associated molecular patterns (DAMPs), and releasing of IFN-γ improves anti-tumor responses115. Depending on the severity and duration of radiotherapy, radiation-induced autophagy shows bi-lateral effects. When the amount of stress is low, autophagy compensates for the complications and makes resistance to radiotherapy (cytoprotective autophagy) and improves tumor cell survival, but with the increase in stress severity autophagic cell death occurs116.

On the subject of BC, autophagy led to an improvement in tumor cell survival when radiotherapy was applied to the MDA-MB-231 cell line through PI3K-Akt mTOR pathway interaction117.

Recent studies have indicated the involvement of miRNA in autophagy-mediated radiation resistance of BC tumor cells116. Meng et al118 showed that miR-26b negatively regulated the DNA damage-regulated autophagy modulator 1 (DRAM1) and made a suppression in autophagy process in MCF-7 cells. Following miR-26b over-expression autophagy was inhibited and sensitization to radiotherapy was increased. Decreased expression of miR-129-5p caused an increase in the expression of HMGB1 and induced irradiation-induced autophagy which protects BC tumor cell survival. Along with the overexpression of miR-129-5p, the sensitization of MDA-MD-231 cells against irradiation was improved119. In another interesting study, Yi et al120 found that miR-199a-5p has a dual regulatory effect on irradiation-induced autophagy via DRAM1 and Beclin1. They showed that by over-expression of miR-199a-5p irradiation-induced autophagy in MCF-7 cells, whereas this miRNA induced irradiation-induced autophagy in MDA-MB-231 cells. Considering the different expression patterns of miR-200c in BC cell lines, Sun et al121 showed that decreased expression of miR-200c has a relation with radioresistance in MDA-MB-231 cells through targeting ubiquilin 1 (UBQLN1) which plays a role in autophagosome formation. Along with the ectopic expression of miR-200c, autophagy was inhibited and radiosensitivity was increased.

**Effects of Autophagy and miRNAs on Endocrine and Targeted therapy of BC**

Endocrine therapy (ET) also called hormone therapy is a type of therapy in which hormones
especially estrogen amounts are decreased, or their functions are blocked. This therapy is used only in hormone-receptor-positive BC patients and involves a variety of medications like tamoxifen, fulvestrant, aromatase inhibitors, etc. ET reduces recurrence and mortality rate in BC patients and not only improves the quality of life but also has the fewest side effects compared to other methods. However, drug resistance limits therapy efficacy. Among the factors that cause ET resistance, changes in intracellular pathways such as autophagy and miRNAs expression patterns are among the important ones. In vitro study proposed miR-101 as an autophagy inhibitor through targeting ATG4D, RAB5A, and STMN1. Overexpression of miR-101 restrained resistance toward 4-hydroxytamoxifen (4-OHT) and increased MCF-7 cells sensitivity. Increased expression of miR-451a suppressed autophagy and improved tamoxifen sensitivity in MCF-7 and LCC2 BC cells via regulation of 14-3-3ζ protein. By disrupting cell amino acids level via targeting an amino acid transporter, Solute Carrier Family 6 Member 14 (SLC6A14), miR-23b-3p induced autophagy and drug resistance in BC against tamoxifen and fulvestrant. Knockdown of miR-21 induced autophagy via suppressing PI3K-AKT-mTOR pathway and increasing Beclin-1 and LC3-II expression level which promoted the sensitivity toward tamoxifen and fulvestrant in MCF-7 cells. MiR-214 was found to suppress autophagy through activation of the PI3K-AKT-mTOR pathway and increasing uncoupling protein 2 (UCP2). Inhibited autophagy increased sensitivity toward tamoxifen and fulvestrant in MCF-7 cells. Regarding targeted therapy, trastuzumab or Herceptin is a monoclonal antibody used for HER-2 positive BC patients in early and advanced stages. MiR-567 showed an inhibitory effect on the autophagy process and resistance to trastuzumab via targeting ATG5 in BC patients and cell lines. Although its expression level is downregulated in trastuzumab-resistant cells, increased expression of miR-567 suppressed autophagy and enhanced the sensitivity to trastuzumab in vitro.

Discussion

In light of the high prevalence, heterogeneity, and resistance to therapy observed in BC, a better understanding of the molecular mechanisms involved in tumor progression and response to therapies could remove existing barriers to therapy development and enable new ones to be developed. It has been shown that autophagy is one of the intracellular degradation pathways implicated in tumorigenesis, responsiveness, or resistance to various therapies in BC. Currently, studies are aimed at identifying therapeutic agents that can target multiple pathways, of which miRNAs are one of the best that have the ability to regulate several pathways including autophagy in multiple steps. Targeting autophagy regulating miRNAs is proposed as a treatment procedure that would increase clinical outcomes and reverse therapy resistance (Table I).

However, due to the bilateral effects of miRNAs studied, it seems that targeting them requires consideration of factors which previous studies have shown their regulatory effects on the expression and effects of miRNAs. The factors currently identified are genetic or epigenetic alterations of DNA sequences that code miRNAs, transcriptional regulation, alterations of mRNA target sites. Hence, there is a possibility that these factors directly or indirectly affect the miRNA’s effect on the autophagy pathway. It would be helpful to consider these factors in targeting autophagy regulating miRNAs. Here, as discussed in the chemotherapy section of the manuscript, miR-181-5p, miR-25, and miR-125 induced autophagy which resulted in enhanced sensitivity to chemotherapy drugs, whereas other miRNAs by inducing autophagy caused drug resistance. In radiotherapy, while overexpression of miR-199-5p caused inhibition in IR-induced autophagy in MCF7 cells, it improved IR-induced autophagy and basal autophagy in MDA-MB-231 cells. Furthermore, miR-20a has presented different results in terms of inducing autophagy and enhancing BC cell progression and/or death.

Conclusions

The importance and role of autophagy-regulating miRNAs in the growth and development of cancer have been demonstrated in recent years. In order to develop an effective therapy based on miRNAs that regulate autophagy in BC, many factors must be taken into account. MiRNA itself, cell line type and induced autophagy effects are some of the things that have been identified by studies so far and further investigations are needed. Although there have been a few cases where
Autophagy-regulating microRNAs: two-sided coin in the therapies of breast cancer

Table I. Effects of autophagy-regulating miRNAs on treatment responses in breast cancer.

<table>
<thead>
<tr>
<th>miRNA</th>
<th>Target</th>
<th>Effect on autophagy</th>
<th>Influence on treatment response</th>
<th>Drug(s)</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chemotherapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-129-5p</td>
<td>HMGB1</td>
<td>Inhibition</td>
<td>Sensitivity-promoting</td>
<td>Paclitaxel</td>
<td>104</td>
</tr>
<tr>
<td>miR-27a</td>
<td>p62</td>
<td>Inhibition</td>
<td>Sensitivity-promoting</td>
<td>Paclitaxel &amp; doxorubicin</td>
<td>106</td>
</tr>
<tr>
<td>miR-18a</td>
<td>mTOR</td>
<td>Promotion</td>
<td>Resistant-promoting</td>
<td>Paclitaxel</td>
<td>107</td>
</tr>
<tr>
<td>miR-489</td>
<td>LAPTM4B</td>
<td>Inhibition</td>
<td>Sensitivity-promoting</td>
<td>Doxorubicin</td>
<td>109</td>
</tr>
<tr>
<td>miR-142-3p</td>
<td>HMGB1</td>
<td>Inhibition</td>
<td>Sensitivity-promoting</td>
<td>Doxorubicin</td>
<td>110</td>
</tr>
<tr>
<td>miR-181a-5p</td>
<td>VDR</td>
<td>Promotion</td>
<td>Sensitivity-promoting</td>
<td>Cisplatin</td>
<td>111</td>
</tr>
<tr>
<td>miR-25</td>
<td>ULK1</td>
<td>Inhibition</td>
<td>Resistant-promoting</td>
<td>Epirubicin</td>
<td>112</td>
</tr>
<tr>
<td><strong>Radiotherapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR 26b</td>
<td>DRAM1</td>
<td>Inhibition</td>
<td>Sensitivity-promoting</td>
<td>-</td>
<td>118</td>
</tr>
<tr>
<td>miR-129-5p</td>
<td>HMGB1</td>
<td>Inhibition</td>
<td>Sensitivity-promoting</td>
<td>-</td>
<td>119</td>
</tr>
<tr>
<td>miR-199a-5p</td>
<td>DRAM1</td>
<td>Inhibition in MCF7</td>
<td>No changes</td>
<td>-</td>
<td>120</td>
</tr>
<tr>
<td>miR-200c</td>
<td>UBQLN1</td>
<td>Inhibition</td>
<td>Sensitivity-promoting</td>
<td>-</td>
<td>121</td>
</tr>
<tr>
<td><strong>Endocrine therapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-101</td>
<td>ATG4D</td>
<td>Inhibition</td>
<td>Sensitivity-promoting</td>
<td>Tamoxifen</td>
<td>82</td>
</tr>
<tr>
<td></td>
<td>STMN1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>RAB5A</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-451a</td>
<td>14-3-3e</td>
<td>Inhibition</td>
<td>Sensitivity-promoting</td>
<td>4-hydroxytamoxifen</td>
<td>125</td>
</tr>
<tr>
<td>miR-23b-3p</td>
<td>SLC6A14</td>
<td>Promotion</td>
<td>Resistant-promoting</td>
<td>Tamoxifen and fulvestrant</td>
<td>126</td>
</tr>
<tr>
<td>miR-21</td>
<td>PTEN</td>
<td>Promotion</td>
<td>Resistant-promoting</td>
<td>Tamoxifen and fulvestrant</td>
<td>127</td>
</tr>
<tr>
<td>miR-214</td>
<td>UCP2</td>
<td>Inhibition</td>
<td>Sensitivity-promoting</td>
<td>Tamoxifen and fulvestrant</td>
<td>128</td>
</tr>
<tr>
<td><strong>Chemotherapy &amp; Endocrine therapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-125b-5p</td>
<td>PAD2</td>
<td>Promotion</td>
<td>Sensitivity-promoting</td>
<td>Docetaxel &amp; tamoxifen</td>
<td>113</td>
</tr>
<tr>
<td><strong>Targeted therapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-567</td>
<td>ATG5</td>
<td>Inhibition</td>
<td>Sensitivity-promoting</td>
<td>Trastuzumab</td>
<td>130</td>
</tr>
</tbody>
</table>

miRNA; microRNAs, HMGB1: high mobility group protein B1, mTOR: mechanistic target of rapamycin, LAPTM4B: lysosomal protein transmembrane 4 beta, VDR: vitamin D receptor, ULK1: Unc-51-like kinases 1, DRAM1: DNA damage regulated autophagy modulator 1, UBQLN1: ubiquilin 1, ATG4: autophagy-related genes 4, SLC6A14: Solute Carrier Family 6 Member 14, PTEN: phosphatase and tensin homolog, UCP2: uncoupling protein 2, ATG5: autophagy-related genes 5.

the results were unexpected, in general, it seems that focusing on autophagy-regulating miRNAs as biomarkers or therapeutic targets could be an important step toward improving BC patients’ therapies.

**Conflict of Interest**
The Authors declare that they have no conflict of interests.

**Funding**
No specific funding was used.

References

5) DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL.


34) Puri C, Renna M, Bento CF, Moreau K, Rubinsztein DC. Diverse autophagosome membrane...
Autophagy-regulating microRNAs: two-sided coin in the therapies of breast cancer


77) Li S, Qiang Q, Shan H, Shi M, Gan G, Ma F, Chen B. MiR-20a and miR-20b negatively regulate autophagy by targeting RB1CC1/FIP200 in breast cancer cells. Life Sci 2016; 147: 143-152.


92) Duan S, Yu S, Yuan T, Yao S, Zhang L. Exogenous Let-7a-5p induces A549 lung cancer cell


97) Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012; 148: 399-408.


119) Luo J, Chen J, He L. mir-129-5p attenuates irradiation-induced autophagy and decreases ra-


